Phase 2b Tuberculosis Trial Doses First Patient with ALPE
Prior data on alpibectir-ethionamide (AlpE) showed a 7-day early bactericidal activity signal comparable to isoniazid and a generally acceptable...
New Gedatolisib Breast Cancer Data from VIKTORIA-1 Study
In the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial in HR+/HER2- advanced breast cancer post-CDK4/6 inhibitor, gedatolisib...
FDA Clears First-Ever Dental MRI After Successful Trial
FDA has cleared the first dental‑dedicated MRI system in the U.S., the MAGNETOM Free.Max Dental Edition, following a clinical...
Profound Medical to Discuss First CAPTAIN Trial Outcomes
No efficacy or safety figures were disclosed. Profound Medical will present the first clinical outcomes from CAPTAIN, a Level...
Bioversys’ New Tuberculosis Trial Results Published in NEJM
A 7-day Phase 2a early bactericidal activity study in pulmonary tuberculosis established clinical proof of concept for alpibectir plus...
ACTG LATITUDE Study Findings Published in New England Journal
Regimen failure through 48 weeks was 22.8% with long-acting cabotegravir plus rilpivirine versus 41.2% with continued daily oral ART...
Dyne Announces Promising Phase 3 HARMONIA Trial for DM1
A 48-week, global, randomized, placebo-controlled Phase 3 trial in myotonic dystrophy type 1 will enroll approximately 150 participants aged...
New Positive Results for Z-rostudirsen in DMD DELIVER Trial
Dyne Therapeutics reported 24-month analyses from the Phase 1/2 DELIVER trial showing improvements from baseline in lung function (FVC...
Dianthus to Discuss Interim Phase 3 CIDP Trial Results
Dianthus Therapeutics will present an interim responder analysis from Part A of its Phase 3 CAPTIVATE trial evaluating claseprubart...
Rhythm Pharma Sees Positive Phase 3 Setmelanotide Trial Data
Setmelanotide delivered an 18.8% placebo‑adjusted difference in BMI reduction at 52 weeks in the Phase 3 TRANSCEND trial’s expanded...